HK Stock Market Move | Baidu Group - W (09888) rose over 5%. After the company's dual primary listing, its market value reassessment may reach one trillion Hong Kong dollars, and the switch in valuation system is worth looking forward to.
Baidu Group-W (09888) rose more than 5%. As of this writing, it is up 4.21%, priced at HKD 95.35, with a trading volume of HKD 767 million.
Baidu Inc Sponsored ADR Class A Group-W (09888) rose over 5%, as of press time, it increased by 4.21% to HKD 95.35, with a trading volume of HKD 767 million.
In news, on September 1, Baidu Inc Sponsored ADR Class A Group (09888, BIDU.US) announced on the Hong Kong Stock Exchange that the previously announced voluntary change of its listing status from secondary to primary listing has taken effect today. Baidu Inc Sponsored ADR Class A is now a dual primary listed company on both the Hong Kong Stock Exchange and the NASDAQ Global Select Market. "Baidu Inc Sponsored ADR Class A is expected to soon see new capital inflows, potentially next week," said He Haijian, Chief Financial Officer of Baidu Inc Sponsored ADR Class A, in an exclusive interview with Bloomberg. Referring to some opinions from brokers and analysts, it is expected that companies of this market capitalization size, like Baidu Inc Sponsored ADR Class A, will see an incremental capital inflow of 10%-15% into the stock.
Zou Chengfeng, Senior Vice President at Dongxing Investment Bank, believes that from an investment banking valuation perspective, one noteworthy change following the dual primary listing of Baidu Inc Sponsored ADR Class A is that its AI assets may achieve more independent pricing. Currently, several institutions in the market are using a segment valuation method to assess Baidu Inc Sponsored ADR Class A. If businesses like Kunlun Chip, Intelligent Cloud, and Run, Radish, Run are valued separately, and considering the growth potential of the AI business, some estimates indicate that Baidu Inc Sponsored ADR Class A has a potential upside of nearly three times, making the switch in the valuation system worth looking forward to.
Related Articles

Roche (RHHBY.US) has received acceptance from the CDE for its marketing application for faricimab injection, intended for the treatment of uveitic macular edema.

Daihe: AKESO (09926) HARMONi-2 mid-term OS analysis met expectations, slightly boosting confidence in global first-line NSCLC phase III trial OS success.

CATHAY PAC AIR (00293) Lin Shaobo: The group's capacity has surpassed pre-pandemic levels, and the target number of destinations will increase to 150 in the next decade.
Roche (RHHBY.US) has received acceptance from the CDE for its marketing application for faricimab injection, intended for the treatment of uveitic macular edema.

Daihe: AKESO (09926) HARMONi-2 mid-term OS analysis met expectations, slightly boosting confidence in global first-line NSCLC phase III trial OS success.

CATHAY PAC AIR (00293) Lin Shaobo: The group's capacity has surpassed pre-pandemic levels, and the target number of destinations will increase to 150 in the next decade.

RECOMMEND





